Results 251 to 260 of about 319,917 (288)

A subset of MMR‐proficient colon cancers responds to neoadjuvant immunotherapy

Molecular Oncology, EarlyView.
Tan et al. reveal that a distinct subset of early‐stage pMMR colon cancers can respond to neoadjuvant immunotherapy. In the NICHE‐2 trial, responders (26%) were characterized by chromosomal instability, TP53 mutations, and proliferative cell‐cycle programs, whereas nonresponders showed metabolic and stromal reprogramming with TGF‐β‐driven ...
Eleonora Piumatti, Giovanni Germano, Pietro Paolo Vitiello, Alberto Bardelli   +3 more
wiley   +1 more source

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

Molecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg, Joachim von Braun, Julio Celis, Anton Berns, Michael Baumann, Tit Albreht, Nancy Abou‐Zeid, Vanderlei Bagnato, Christian Brandts, Chien‐Jen Chen, Massimiliano di Pietro, Manjit Dosanjh, Thomas Dubois, Alexander Eggermont, Angelika Eggert, Ingemar Ernberg, Sara Faithfull, Johannes Förner, Stefan Fröhling, Manuel Heitor, Leroy Hood, Wei Jiang, Bengt Jönsson, Ravi Kannan, Maria Leptin, Su Li, Peter Lindgren, Douglas Lowy, Jun Ma, Alex Markham, Péter Nagy, Simon Oberst, M. Iqbal Parker, Danielle Rodin, Kevin Ryan, Joachim Schüz, Richard Sullivan, Josep Tabernero, Peter Turkson, Oliver Várhelyi, Harold Varmus, Chijie Wang, Elisabete Weiderpass, Nils Wilking   +43 more
wiley   +1 more source

A Bottom-Up Synthetic Approach to Polyethylene Furanoate Model Compounds. [PDF]

J Org Chem
Mondal K, Dharaniyedath J, Müller BH, Spannenberg A, Klahn M, Francke R.   +5 more
europepmc   +1 more source

Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD‐L1 in melanoma

Molecular Oncology, EarlyView.
Using cell surface proximity biotinylation, we identified tetraspanin TSPAN4 within the PD‐L1 interactome of melanoma cells. TSPAN4 negatively regulates PD‐L1 expression and lateral mobility by limiting its interaction with CMTM6 and promoting PD‐L1 degradation.
Guus A. Franken, Andrea Abel Gutierrez, Imke van Rossum, Cornelia G. Spruijt, Michiel Vermeulen, Guido van Mierlo, Blanca Scheijen, Annemiek B. van Spriel   +7 more
wiley   +1 more source

Who remains uncovered? Assessing inequalities and determinants of national health insurance enrolment among informal sector workers in Kenya. [PDF]

Glob Health Res Policy
Wamalwa PN, Strupat C, Singh K, Kuloba MN, Kazungu J, De Allegri M.   +5 more
europepmc   +1 more source

Subschemes of group association schemes /

, 1990
Yasushi Iwakata
openalex   +1 more source

Control, access and professionalism: a qualitative evaluation of Australian dental practitioners attitudes to expanding medicare to include more dental services. [PDF]

BMC Oral Health
Holden ACL, Hopcraft MS.
europepmc   +1 more source

The Cut-Off Phenomenon in Random Walks on Association Schemes

, 1996
Akihito Hora
openalex   +1 more source

Robot Object Detection and Tracking Based on Image-Point Cloud Instance Matching. [PDF]

Sensors (Basel)
Wang H, Zhu R, Ye Z, Li Y.
europepmc   +1 more source

Changes in the Interaction Properties of Antibodies with Fc Receptors upon Binding to Target Antigens. [PDF]

Biosensors (Basel)
Grevtsev AS, Kommer AA, Zelmanchuk IS, Avdiushkin AS, Ermolaeva EO, Tiulin AA, Chernyshova DO, Azarian AD, Gordeev AA, Misorin AK.   +9 more
europepmc   +1 more source